133 related articles for article (PubMed ID: 7666078)
1. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
3. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
4. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
5. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
7. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
8. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
9. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
[TBL] [Abstract][Full Text] [Related]
12. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
[TBL] [Abstract][Full Text] [Related]
13. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
[TBL] [Abstract][Full Text] [Related]
14. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
17. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
20. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
